Dextera Surgical Inc. (NASDAQ:DXTR) was the target of a large decrease in short interest in October. As of October 31st, there was short interest totalling 908,603 shares, a decrease of 79.7% from the October 13th total of 4,483,023 shares. Based on an average daily trading volume, of 9,734,394 shares, the short-interest ratio is presently 0.1 days. Approximately 1.9% of the shares of the stock are short sold.

A number of institutional investors and hedge funds have recently made changes to their positions in DXTR. Perkins Capital Management Inc. bought a new position in Dextera Surgical in the 2nd quarter valued at $100,000. Virtu KCG Holdings LLC boosted its position in Dextera Surgical by 1,380.6% in the 2nd quarter. Virtu KCG Holdings LLC now owns 369,918 shares of the medical instruments supplier’s stock valued at $111,000 after buying an additional 344,933 shares during the last quarter. Finally, Broadfin Capital LLC boosted its position in Dextera Surgical by 64.7% in the 2nd quarter. Broadfin Capital LLC now owns 987,520 shares of the medical instruments supplier’s stock valued at $296,000 after buying an additional 388,080 shares during the last quarter. Hedge funds and other institutional investors own 6.21% of the company’s stock.

Shares of Dextera Surgical (NASDAQ DXTR) opened at $0.16 on Friday. Dextera Surgical has a twelve month low of $0.11 and a twelve month high of $2.33.

Dextera Surgical (NASDAQ:DXTR) last released its quarterly earnings results on Thursday, November 9th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.02). The company had revenue of $0.69 million during the quarter, compared to analysts’ expectations of $0.62 million. sell-side analysts expect that Dextera Surgical will post -0.25 EPS for the current year.

A number of brokerages have recently issued reports on DXTR. Zacks Investment Research cut Dextera Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Ladenburg Thalmann Financial Services began coverage on Dextera Surgical in a report on Wednesday, August 16th. They issued a “buy” rating and a $0.80 target price for the company.

WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at

Dextera Surgical Company Profile

Dextera Surgical Inc, formerly Cardica, Inc, designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.

Receive News & Stock Ratings for Dextera Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical Inc. and related stocks with our FREE daily email newsletter.